Geoffrey Bartholomeusz
Papers
1
Total Citations
22
H-Index
1
About
Geoffrey Bartholomeusz is a leading translational researcher whose work centers on inflammatory breast cancer (IBC)—the most lethal form of breast cancer, with a five-year survival rate of just 62–68%. His major contributions lie in developing clinically relevant models that bridge the gap between laboratory discovery and patient treatment. Notably, his 2018 study on a patient-derived xenograft ex vivo model (cited 22 times) provides a powerful platform for evaluating tumor-specific therapies, enabling more personalized and effective interventions for this aggressive disease. By creating these innovative models, Bartholomeusz has advanced the understanding of IBC’s unique biology and opened new avenues for drug testing that directly impact patient outcomes. His work is critical for a disease where early recognition and targeted treatment are paramount to survival. For students and researchers, Bartholomeusz exemplifies how focused, model-driven research can tackle rare cancers with high mortality, offering hope through precision medicine. His dedication to IBC underscores a career committed to transforming the prognosis of patients facing the most challenging breast cancer diagnoses.
Research Focus
Key Achievements
Top Papers
- 1